Nektar maintained by Merrill at buy

Nektar Therapeutics Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy rating with a price target on the stock of $28 per share in advance of a Sept. 8 FDA advisory panel discussion that could result in a favorable outcome for the inhalable insulin powder Exubera. Nektar shares Wednesday were up $0.38, or 2.28%, at $17.08 on volume of 1,122,684 shares versus the three-month running average of 986,509 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.